Bioventix (LON:BVXP) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?

Bioventix PLC (LON:BVXP) shares crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 1,698.59 and traded as high as GBX 1,750. Bioventix shares last traded at GBX 1,711, with a volume of 3,328 shares traded.

Bioventix Stock Performance

The stock has a market capitalization of £89.40 million, a price-to-earnings ratio of 12.18 and a beta of 0.55. The company has a fifty day simple moving average of GBX 1,698.59 and a 200 day simple moving average of GBX 1,697.74.

Bioventix (LON:BVXP) last announced its earnings results on Monday, March 30th. The biotechnology company reported GBX 69.38 EPS for the quarter. The firm had revenue of GBX 615.88 billion for the quarter. Bioventix had a return on equity of 65.83% and a net margin of 59.30%. As a group, equities analysts predict that Bioventix PLC will post 166.3066955 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Bruce Hiscock bought 66 shares of the business’s stock in a transaction on Monday, April 27th. The shares were purchased at an average cost of GBX 1,679 per share, with a total value of £1,108.14. Also, insider Peter John Harrison bought 1,065 shares of the company’s stock in a transaction that occurred on Wednesday, April 8th. The stock was purchased at an average price of GBX 1,849 per share, for a total transaction of £19,691.85. In the last three months, insiders have purchased 2,131 shares of company stock valued at $3,927,999. 6.22% of the stock is currently owned by company insiders.

Bioventix Company Profile

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.